Blog

October 2014: Eagle Biosciences Introduces New Antibody Drug Conjugate ELISA Assays

 

Nashua, NH:
Eagle Biosciences is now offering unique Antibody Drug Conjugate (ADC) ELISA
Assay Kit menu including MMAE Antibody Drug Conjugate (ADC) ELISA, MMAF
Antibody Drug Conjugate (ADC) ELISA, and DM1 Antibody Drug Conjugate (ADC)
Assay ELISA. These assays will
complement and further expand their current immunology assay portfolio.

The ADC ELISA
Assay kits have excellent sensitivity, wide dynamic range, and can be used with
multiple species and sample types. These
analytes provide incredible value to pre-clinical and clinical pharmacology
studies, cancer research, and more specifically tumor marker investigation. In addition, each of these assays offer
simple procedure with quick results.

“We are
excited to bring the ADC kits to the market.” said Dan Keefe, President of
EagleBio. He continued, “These assays
will help EagleBio reach new emerging market segments in cancer research and
help us to fulfill unmet needs in the field.”

These
products are currently for research use only. Check out the list of Antibody
Drug Conjugate ELISA Assay Kits below. In addition, the antibodies used in
these kits are available for purchase upon special request.
  Visit the Eagle website, or
call 866-411-8023 for full details.

 

MMAE Antibody Drug Conjugate (ADC) ELISA Assay Kit

MMAF Antibody Drug Conjugate (ADC) ELISA Assay Kit

DM1 Antibody Drug Conjugate (ADC) ELISA Assay Kit

Ingestion of Stool…A Promising Therapy for C. difficile Infection

In search of palatable poo

C. difficile
infections are horribly uncomfortable for patients causing painful
bloating,
cramping, and excessive diarrhea. In
fact, certain strains of C. difficile cause about 250,000
hospitalizations and
14,000 deaths each year in the U.S. The quest for new types of therapy
is because of two big dilemmas with regards to antibiotic treatment.
There is increased antibiotic resistance and they
have a detrimental effect on normal gut flora which protect the body
from
harmful pathogens. So
here’s the scoop…there’s now hope with ingesting poop!

Many of you
are probably thinking…ingesting stool that sounds rather disgusting but in fact
it is actually pretty brilliant! This
unique treatment has been the focus of current study at Massachusetts General Hospital
(MGH). A recent press release from the hospital describes this study’s objective to
investigate whether delivering FMT orally through capsules designed to open
upon reaching the small intestine would be just as effective as other more
invasive treatments such as delivering frozen fecal material for FMT either by
colonoscopy or nasogastric tube.


image above from:

A potential role of circulating LHCGR forms for the prediction of preeclampsia in the first trimester of pregnancy

A recent abstract pertaining to using LHCGR forms for the prediction of preeclampsia was presented at the 13th World Congress in Fetal Medicine. The World Congress is designed both for those specializing in
fetal-maternal medicine and those with a more general clinical interest
who want to be updated on developments in the field. Leading
international experts and young researchers present and discuss the
latest developments in fetal medicine. 

Objective
To explore the possible role of circulating human chorionic gonadotrophin receptor (LHCGR) forms in the prediction of early and late preeclampsia (PE) in the first trimester of pregnancy, combined with maternal baseline risk, biophysical parameters and angiogenic factors.

Methods
A case-control study, within a cohort of 5, 759 pregnancies including 20 cases of early PE, 20 of late PE (cut-off: 34 weeks at delivery), 300controls. Maternal characteristics, mean arterial pressure (MAP), uterine artery (UtA) Doppler (11-13 weeks), placental growth factor (PlGF),soluble Fms-like tyrosine kinase-1 (sFtl-1), circulating sLHCGR, and hCG-LHCGR complexes (8-11 weeks) were measured/recorded.  LHCGR difference (LHCGR-D) was calculated by subtracting hCG-LHCGR value from the corresponding sLHCGR. All parameters were normalized by logarithmic transformation, converted in MoM, and logistic regression analysis was used to predict PE.

Conclusion
Among LHCGR forms, the LHCGR-D improves substantially the prediction for early and late PE in first trimester, if used in algorithms. These new biomarkers seemed useful if used in combination (LHCGR-D) in the context of prediction of PE.

 

READ Entire AACC Scientific Abstract HERE

 

 

 

October, 2014: Matriks Biotek Introduces Eagle Biosciences, Inc. as Distributor in North America

MMAE Antibody Drug Conjugate (ADC) ELISA Assay Kit

 

 

Eagle Biosciences recently announced a North American distribution agreement with Matriks Biotek. Matriks develops and manufactures unique ELISA test kits and monoclonal antibodies with a strong focus on meeting research needs and creating products to better understand a variety of diseases and conditions in areas such as inflammation, immunology, gastrology, oncology, diabetes and obesity, and reproductive science.

“Matriks Biotek products bring a multitude of esoteric products to EagleBio.” said Dan Keefe President of EagleBio. He continued, “This is a great collaboration with respect to EagleBio’s goals to continually seek out quality, unique scientific tools and Matriks Biotek’s quest for R&D innovations and special interest for biotherapeutics and novel markers for diseases.” Keefe continued, “We are especially excited about Matriks’ Shikari® ELISA kits and anti-drug antibody ELISA assay kit product line.” He continued, “These can be efficiently used, for monitoring serum trough levels and the presence of anti-drug antibodies respectively.”

These products are currently for research use only. Check out the list of Matrik Biotek products below. Visit the Eagle website www.EagleBio.com or call 866-411-8023 for full details.

Infliximab (Remicade®) Antibodies ELISA Assay kit

Free Adalimumab (Humira®) ELISA Assay Kit

Adalimumab (Humira®) Antibodies ELISA Assay Kit

Etanercept (Enbrel®) ELISA Assay Kit

Etanercept (Enbrel®) Antibodies ELISA Assay Kit

Bevacizumab (Avastin®) ELISA Assay Kit

Bevacizumab (Avastin®) Antibodies ELISA Assay Kit

Trastuzumab (Herceptin®, Herclon®).ELISA Assay Kit

Trastuzumab (Herceptin®, Herclon®) Antibodies ELISA Assay Kit

 

New Study Focuses On Designing Novel Antibodies to Target Breast Cancer Cells


image from www.pinkribbonblues.org

In honor of breast cancer awareness month, we thought we would
share some interesting and hopeful new research. But before discussing
this we should take some time to reflect on the fact that people
afflicted by this disease are battling it everyday and some for
several years. It does seem trivial to only recognize it one month of
every year when you consider all of this, but perhaps this is our way of
setting time aside to focus attention and in some way bring energy,
good vibes, and perhaps fresh ideas to conquer this disease.

A recent study done by the University of Michigan focused on
selecting novel monoclonal antibodies with anticancer activity. They
did this by creating an environment of cancer cells in vitro and then
exposing these cells to numerous antibodies to evaluate if these
antibodies have any anti-cancer fighting effects. How they created the
antibodies is rather intriguing. Read more
.

Sensitivity of Islet Cell Antibodies (ICA) ELISA Compared with Indirect Immunofluorescence Assay

Type 1 diabetes, also known as insulin-dependent diabetes mellitus, results from a chronic autoimmune process which destructs the insulin-secreting pancreatic beta cells. Before the onset of disease T1D patients may demonstrate autoantibodies against different autoantigens of islet cells. Research indicates that these autoantibodies have been shown to be important markers for the identification of individuals with an increased risk to develop T1D at a time when all metabolic tests available still show normal results.

Islet cell autoantibodies detected by indirect immunofluorescence (IIF) have been the first serological markers described for T1D. This technique using tissue sections from human or primate pancreas, however, still reveals methodological problems, especially with regard to inter-laboratory standardization. After discovery of the two main protein antigens of ICA – the enzyme glutamic acid decarboxylase (GAD65) and the islet cell protein IA2 – it has been possible to measure these specific autoantibodies by radioligand assays and recently by sensitive ELISA.

Risk assessment of T1D can be achieved by the combination of tests for these different autoantibodies. Therefore, the Eagle Biosciences ICA screen ELISA Assay kit – designed for the semiquantitative determination of ICA to enable reliable screening – was compared with IIF as the routine method for the detection of ICA.


Conclusion:

The Eagle Biosciences ICA screen ELISA Assay Kit is a robust and sensitive tool for the detection of ICA. In comparison with established methods for the detection of ICA, this assay showed superior sensitivity. These data strongly support further investigation to confirm the better sensitivity of the ICA screen ELISA.

 

 

  • READ Entire AACC Scientific Poster Presentation HERE
  • Review Eagle Biosciences ICA Screen ELISA Assay Kit Product Page
New Discovery that Makes Growing Replacement Organs a Possibility

The
very thought of being able to grow actual human organs in a laboratory is mind
blowing! There are endless possibilities
for medical research with a recent study performed at the MRC Centre of
Regenerative Medicine in Edinburgh, U.K. Scientists were successfully able to cultivate living cells from an
animal in vitro. The process that they used to do this could
be used for a multitude of medical purposes and therapies for transplant
patients and more. This study was
focused on creating a functional thymus for mice but it brings hope that this process could be
used for humans for creating a variety of other organ tissues. Read more.

Credit: MRC Centre for Regenerative Medicine, University of Edinburgh

New Promotion Available Through the End of October for Catecholamine Assays:

 

 

Dopamine Sensitive ELISA

For
the quantitative and very sensitive determination of dopamine in
biological samples including serum, plasma, tissue, and cell culture
samples. Also appropriate for mouse/rat samples. Sample sizes as small
as 20µl with detection limits to 5.9 pg/mL.

Noradrenaline Sensitive ELISA

For
the quantitative and very sensitive determination of noradrenaline in
biological samples including serum, plasma, tissue, and cell culture
samples or even mouse/rat samples. Sample sizes as small as 20µl with
detection limits to 1.0 pg/mL.

Adrenaline Sensitive ELISA

For
the quantitative and very sensitive determination of adrenaline in
biological samples including serum, plasma, tissue, and cell culture
samples and even rodent samples. Sample sizes as small as 20µl with
detection limits to 1.6 pg/mL. 

Serotonin Sensitive ELISA

The Serotonin Ultrasensitive ELISA Assay Kit
provides materials for the quantitative measurement of serotonin in low
concentrated samples, for small sample volumes or for many different
species samples.

These
catecholamine kits have been successfully utilized in many different
species and sample types. Please contact Eagle Biosciences at info@eaglebio.com or 617-419-2019 for details.

Other Catecholamine Assay kits from Eagle Biosciences:

 

  • VMA ELISA
  • HVA ELISA
  • Adrenaline ELISA
  • Dopamine ELISA
  • Noradrenaline ELISA

 

Pancreatic
cancer still continues to have a bleak prognosis despite many advances in
chemotherapy and surgical procedures .In
fact, pancreatic cancer has the worst survival rate of all cancers with only a
small percentage surviving over 5 years after diagnosis. Now, researchers at
the University of Missouri have discovered that a molecule that can used as a
communication system by bacteria can be manipulated to prevent cancer cells
from not only spreading but possibly killing them all together. Read more This
study demonstrated that using such a molecule to combat cancer decreases cell
viability, promotes apoptosis by activating caspases, and inhibits the wound
healing process. It shows amazing
promise for pancreatic cancer however, further research is needed in vivo. Read more

Funding
for pancreatic cancer has increased over the last several years yet it still
only gets one percent of research funding. How is this possible…one of the most
deadly cancers receives only ONE PERCENT of funding?!  Pancreatic cancer is severely underfunded
just like Alzheimer’s as we mentioned in one of our previous blogs, 10 Reasons to Keep with your Vitamin D Levels. We
chose to highlight this new pancreatic cancer research in this blog not only
because it is a significant step towards a cure but also because some folks
from Eagle Biosciences will be walking this weekend in the New England Pancreatic Research Walk in
support of the cause and to support a friend who has lost a loved one.

Lustgarten Foundation is
a private foundation created by Cablevision to
dedicate funding pancreatic research. Cablevision underwrites all of the
foundations costs so that 100% of every donation goes to this research. If you
want to donate to the Lustgarten Foundation Click here or
to donate to the personal cause that we walk for this weekend Click here.

Image from www.sciencedaily.com

 

 

 

 

New Technology:  Aqueous Two Phase System Patterning of Dectection Antibody Solutions for Cross-Reaction Free Multiplex ELISA

Accurate disease diagnosis, patient stratification and biomarker validation require the analysis of multiple biomarkers. This paper describes cross-reactivity-free multiplexing of enzyme-linked immunosorbent assays (ELISAs) using aqueous two-phase systems (ATPSs) to confine detection antibodies at specific locations in fully aqueous environments. Antibody cross-reactions are eliminated because the detection antibody solutions are co-localized only to corresponding surface-immobilized capture antibody spots. This multiplexing technique is validated using plasma samples from allogeneic bone marrow recipients. Patients with acute graft versus host disease (GVHD), a common and serious condition associated with allogeneic bone marrow transplantation, display higher mean concentrations for four multiplexed biomarkers (HGF, elafin, ST2 and TNFR1) relative to healthy donors and transplant patients without GVHD. The antibody co-localization capability of this technology is particularly useful when using inherently cross-reactive reagents such as polyclonal antibodies, although monoclonal antibody cross-reactivity can also be reduced. Because ATPS-ELISA adapts readily available antibody reagents, plate materials and detection instruments, it should be easily transferable into other research and clinical settings.